Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $7.69 in the prior trading day, Tango Therapeutics Inc (NASDAQ: TNGX) closed at $7.76, up 0.91%. In other words, the price has increased by $0.91 from its previous closing price. On the day, 1.11 million shares were traded. TNGX stock price reached its highest trading level at $7.93 during the session, while it also had its lowest trading level at $7.75.
Ratios:
Our goal is to gain a better understanding of TNGX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.75 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $11.
On July 17, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 25 ’25 when Third Rock Ventures IV, L.P. sold 500,000 shares for $8.02 per share. The transaction valued at 4,008,500 led to the insider holds 13,863,975 shares of the business.
Third Rock Ventures IV, L.P. bought 500,000 shares of TNGX for $3,900,000 on Sep 25 ’25. On Sep 16 ’25, another insider, Third Rock Ventures IV, L.P., who serves as the 10% Owner of the company, sold 363,541 shares for $7.04 each. As a result, the insider received 2,559,329 and left with 14,363,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 863379520 and an Enterprise Value of 717602496. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.53 while its Price-to-Book (P/B) ratio in mrq is 6.38. Its current Enterprise Value per Revenue stands at 29.536 whereas that against EBITDA is -4.636.
Stock Price History:
The Beta on a monthly basis for TNGX is 1.68, which has changed by 0.11015737 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $8.80, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 10.39%, while the 200-Day Moving Average is calculated to be 96.32%.
Shares Statistics:
The stock has traded on average 1.98M shares per day over the past 3-months and 2249590 shares per day over the last 10 days, according to various share statistics. A total of 110.87M shares are outstanding, with a floating share count of 64.33M. Insiders hold about 42.63% of the company’s shares, while institutions hold 73.26% stake in the company. Shares short for TNGX as of 1757894400 were 26798166 with a Short Ratio of 13.57, compared to 1755216000 on 25156715. Therefore, it implies a Short% of Shares Outstanding of 26798166 and a Short% of Float of 28.9.
Earnings Estimates
A comprehensive evaluation of Tango Therapeutics Inc (TNGX) is underway, with the input of 8.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.25 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$0.95 and -$1.49 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.42, with 7.0 analysts recommending between -$1.1 and -$1.83.
Revenue Estimates
8 analysts predict $41.34M in revenue for. The current quarter. It ranges from a high estimate of $53.81M to a low estimate of $3.18M. As of. The current estimate, Tango Therapeutics Inc’s year-ago sales were $11.61M
A total of 8 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $62.4M, while the lowest revenue estimate was $14.94M, resulting in an average revenue estimate of $53.92M. In the same quarter a year ago, actual revenue was $42.07M
